Buskirk S J, Gunderson L L, Adson M A, Martinez A, May G R, McIlrath D C, Nagorney D M, Edmundson G K, Bender C E, Martin J K
Int J Radiat Oncol Biol Phys. 1984 Nov;10(11):2013-23. doi: 10.1016/0360-3016(84)90198-6.
Twenty patients with carcinoma of the gallbladder (GB-4 patients) or extrahepatic bile ducts (EHBD-16 patients) received radiation therapy with curative intent between January, 1980 and December, 1982. All 20 received 4500-5000 rad in 180-200 rad fractions to the tumor and regional lymph nodes. A 1000 to 1500 rad external beam boost was delivered in 180-200 rad fractions in 10 patients who received external beam alone or concomitant 5-Fluorouracil (5-FU). Three of the four GB and 5 of the 16 EHBD patients received a transcatheter boost with 192-Iridium (192Ir) to a dose of 2000-2500 rad calculated at a 0.5-0.1 cm radius. An additional 2 patients with EHBD lesions received an intraoperative electron (IORT) boost of 1500-2000 rad in one fraction calculated to the 90% isodose. Survival and patterns of failure were analyzed by site and treatment method. All four patients with GB carcinoma are dead of disease at 5 1/2, 6, 9 and 10 months from the date of diagnosis respectively. Three of the four developed diffuse peritoneal carcinomatosis. Five of the 16 patients with EHBD carcinoma are alive with a median follow-up of 18 months (range 6-23 months). Four of the 5 patients received a transcatheter 192Ir or IORT boost and all are without evidence of disease. Four of 9 patients who had a subtotal resection with transection of tumor, dilatation of the bile ducts with probes or curettement of the bile ducts developed either diffuse peritoneal carcinomatosis (3 patients) or a recurrence in the surgical scar (2 patients). Local failure was documented in 3 of the nine patients treated with external beam alone +/- 5-FU, and has been documented in one of the seven patients who received an IORT or transcatheter 192Ir boost. Further experience is necessary to determine whether this aggressive treatment will result in long-term disease-free survival in these patients.
1980年1月至1982年12月期间,20例胆囊癌患者(4例胆囊癌患者)或肝外胆管癌患者(16例肝外胆管癌患者)接受了根治性放疗。所有20例患者均接受4500 - 5000拉德的剂量,分180 - 200拉德的分次照射肿瘤及区域淋巴结。10例仅接受外照射或同时接受5 - 氟尿嘧啶(5 - FU)治疗的患者,接受了1000至1500拉德的外照射加量,分180 - 200拉德的分次进行。4例胆囊癌患者中的3例以及16例肝外胆管癌患者中的5例接受了经导管192 - 铱(192Ir)加量,剂量为2000 - 2500拉德,计算半径为0.5 - 0.1厘米。另外2例肝外胆管病变患者接受了术中电子束(IORT)加量,单次剂量为1500 - 2000拉德,计算至90%等剂量线。按部位和治疗方法分析了生存率和失败模式。4例胆囊癌患者分别在诊断后5.5个月、6个月、9个月和10个月死于疾病。4例中有3例发生了弥漫性腹膜癌转移。16例肝外胆管癌患者中有5例存活,中位随访时间为18个月(范围6 - 23个月)。5例患者中有4例接受了经导管192Ir或IORT加量,且均无疾病证据。9例接受肿瘤横断的次全切除术、用探子扩张胆管或刮除胆管的患者中,有4例发生了弥漫性腹膜癌转移(3例)或手术瘢痕复发(2例)。仅接受外照射±5 - FU治疗的9例患者中有3例记录有局部失败,接受IORT或经导管192Ir加量的7例患者中有1例记录有局部失败。需要进一步的经验来确定这种积极的治疗是否会使这些患者获得长期无病生存。